In general, our results confirmed that the AKT-GSK3β-c-Myc-HK2 was the critical pathway regulated by the dose-dependent Daurisoline in lung cancer cells, and we proved Daurisoline was the potential therapeutic oncology drug. This evidence concerns the gene AKT1 and lung carcinoma.